Literature DB >> 34854012

Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones.

Natália Fernandes Mezzomo1, Izaviani da Silva Schmitz2, Valtieri Bortoluzzi de Lima1, Gilson Pires Dorneles3, Larissa Finger Schaffer2, Carina Rodrigues Boeck1, Pedro Roosevelt Torres Romao3, Luis Ricardo Peroza4,5.   

Abstract

BACKGROUND: Schizophrenia is a mental illness and its pharmacological treatment consists in the administration of antipsychotics like haloperidol. However, haloperidol often causes extrapyramidal motor disorders such as tardive dyskinesia (TD). So far, there is no effective treatment against TD and alternatives for it have been sought. Isoflafones have been studied as neuroprotector and inhibitor of monoamine oxidase enzyme. Thus, the objective is to evaluate the possible protective effect of isoflavones against the induction of involuntary movements induced by haloperidol in an animal model. METHODS AND
RESULTS: Male Wistar rats were treated with haloperidol (1 mg/kg/day) and/or isoflavones (80 mg/kg) for 28 days. Rats were submitted to behavioral evaluation to quantify vacuous chewing movements (VCM) and locomotor activity. In addition, the levels of pro-inflammatory cytokines were measured in the striatum. Haloperidol treatment reduced the locomotor activity and increased the number of VCM in rats. Co-treatment with isoflavones was able to reverse hypolocomotion and reduce the number of VCM. Besides, haloperidol caused significant increase in the proinflammatory cytokines (interleukin-1β:IL-1β, tumor necrosis factor-α: TNF-α and IL-6 and the co-treatment with isoflavones was able to reduce the levels of IL-1β and TNF-α, but not IL-6.
CONCLUSIONS: It is believed that the beneficial effect found with this alternative treatment is related to its anti-inflammatory potential and to the action on estrogen receptors (based on scientific literature findings). Finally, further studies are needed to elucidate the mechanisms of isoflavones in reducing motor disorders induced by antipsychotics.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Antipsychotics; Isoflavones; Neuroinflammation; Tardive dyskinesia

Mesh:

Substances:

Year:  2021        PMID: 34854012     DOI: 10.1007/s11033-021-07003-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  3 in total

1.  Potential drug-drug interaction in Mexican patients with schizophrenia.

Authors:  María Conchita Ocaña-Zurita; Isela E Juárez-Rojop; Alma Genis; Carlos Alfonso Tovilla-Zárate; Thelma Beatriz González-Castro; María Lilia López-Narváez; María Elena de la O de la O; Humberto Nicolini
Journal:  Int J Psychiatry Clin Pract       Date:  2016-08-23       Impact factor: 1.812

2.  Estradiol and selective estrogen receptor agonists differentially affect brain monoamines and amino acids levels in transitional and surgical menopausal rat models.

Authors:  Tao Long; Jeffrey K Yao; Junyi Li; Ziv Z Kirshner; Doug Nelson; George G Dougherty; Robert B Gibbs
Journal:  Mol Cell Endocrinol       Date:  2019-08-05       Impact factor: 4.102

3.  Soybean isoflavone ameliorates cognitive impairment, neuroinflammation, and amyloid β accumulation in a rat model of Alzheimer's disease.

Authors:  Amina E Essawy; Heba Mohamed Abdou; Hania M Ibrahim; Najya M Bouthahab
Journal:  Environ Sci Pollut Res Int       Date:  2019-07-05       Impact factor: 4.223

  3 in total
  1 in total

1.  NLRP3/Caspase-1-Mediated Pyroptosis of Astrocytes Induced by Antipsychotics Is Inhibited by a Histamine H1 Receptor-Selective Agonist.

Authors:  Meng He; Jun Fan; Ruqin Zhou; Guanbin Gao; Ruoxi Li; YuFeng Zuo; Benben Li; Yanmei Li; Taolei Sun
Journal:  Front Aging Neurosci       Date:  2022-05-09       Impact factor: 5.702

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.